MCRB — Seres Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1609809 ·
Last close
$6.11
Market Cap
$59.17M
52W High
$9.14
52W Low
$5.31
ADV30
112,173
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 358,000 | 358,000 | -20,907,000 | -19,913,000 | 117,618,000 | 29,834,000 | 91,119,000 |
| Dec 2025 | 789,000 | 197,000 | -19,377,000 | -15,335,000 | 138,193,000 | 45,766,000 | 93,975,000 |
| Sep 2025 | 0 | -736,000 | -22,477,000 | 8,204,000 | 143,473,000 | 47,638,000 | 99,776,000 |
| Jun 2025 | 0 | -1,689,000 | -24,881,000 | -19,855,000 | 143,800,000 | 45,379,000 | 110,850,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,117,000
Investing CF
$-42,000
Financing CF
$13,898,000
CapEx
$-252,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$14.05
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-972,403,000
Inventory
—
Receivables
$517,000
ST Investments
—
EBIT TTM
$70,640,000
Pretax Income TTM
$5,696,000
Interest Exp TTM
$0
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,147,000
EBITDA
$-83,804,000
Free Cash Flow
$-41,538,248
Enterprise Value
$115,934,712
Total Cash
$29,834,000
Total Debt
$80,499,000
Shares Out
9,683,934
Trailing EPS
$-5.20
Book Value
$2.76
ROE
-121.9%
ROA
-38.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 789,000 | -93,971,000 | 5,696,000 | 138,193,000 | 93,975,000 | — | 1,117,000 |
| Dec 2024 | 0 | -121,315,000 | 136,000 | 139,810,000 | 126,026,000 | — | -148,609,000 |
| Dec 2023 | 0 | -195,097,000 | -113,724,000 | 358,600,000 | 403,456,000 | — | -117,354,000 |
| Dec 2022 | 0 | -179,914,000 | -250,157,000 | 348,784,000 | 338,001,000 | — | -228,816,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BYSI | BeyondSpring Inc. | $59.21M | $1.44 | — |
| XLO | Xilio Therapeutics, Inc. | $59.83M | $9.10 | — |
| CLCS | Cell Source, Inc. | $58.48M | $0.86 | — |
| CNTX | Context Therapeutics Inc. | $59.99M | $0.65 | — |
| FLNA | FILANA THERAPEUTICS, INC. | $57.00M | $1.18 | — |
News headlines (Yahoo Finance, 1h cache)
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
2026-07-10 18:02 · Yahoo
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Hal
2026-07-08 11:00 · Yahoo
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
2026-06-25 11:00 · Yahoo
We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate
2026-06-13 12:57 · Yahoo
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
2026-06-05 11:00 · Yahoo
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-12 11:00 · Yahoo
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-05 11:00 · Yahoo
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
2026-05-04 11:00 · Yahoo
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
2026-04-20 11:00 · Yahoo
Seres Therapeutics to Present at CARB-X Investor Day
2026-04-09 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.